Mobia Medical set terms for a $150 million IPO this week, marking the first pure-play nerve stimulation device maker to price since Nevro Corp shed 56% from its 2021 peak. The Morrisville, North Carolina company holds investigational-stage technology for non-opioid pain management but carries no revenue, no FDA clearance, and no distribution agreements into a market where reimbursement codes determine viability.
The offering surfaces during a twelve-month window in which medtech IPO proceeds fell 41% year-over-year, per Renaissance Capital tracking through Q4 2024. Mobia's timing reflects either opportunistic venture exit mechanics or legitimate confidence in neuromodulation's secular tailwinds—the global spinal cord stimulation market runs at a 7.2% CAGR through 2030, driven by opioid-alternative mandates from Medicare Advantage plans. The company's lead device targets chronic back pain, a $635 billion annual U.S. cost burden, but clinical trial readouts remain six quarters out and commercialization likely extends into 2027.
The structural question for allocators: whether Mobia's technology differentiation justifies pre-revenue pricing in a category where Boston Scientific and Medtronic command 68% combined market share. Nevro's collapse—from a $4.8 billion peak valuation to $1.1 billion today—demonstrates how quickly reimbursement headwinds and sales execution misses compress multiples when clinical superiority fails to translate into durable margin expansion. Mobia's S-1 filing discloses $89 million in net losses since inception, with cash burn accelerating as it funds two pivotal trials. The IPO proceeds fund commercialization infrastructure and working capital, standard language that signals eighteen months of runway before either a follow-on raise or partnership necessity.
Family offices and strategic allocators should watch three catalysts with specific timing. First, Mobia's pivotal trial interim data releases in Q3 2025, which will either validate differentiated efficacy claims or expose the device as incrementally better at best. Second, CMS's proposed 2026 physician fee schedule drops in July 2025, and any neuromodulation reimbursement code adjustments will reprice the entire sector within trading days. Third, Boston Scientific's acquisition appetite—the company deployed $1.2 billion on tuck-in medtech deals in 2024—and whether Mobia's technology merits inbound interest before it faces commercialization risk.
The IPO prices into a market where medtech valuations compress 22% from 2021 peaks, but neuromodulation's non-opioid positioning holds optionality that pure orthopedic or cardiovascular plays lack. The risk is execution.